A Retrospective Real-World Study on the Efficacy and Safety of Anlotinib Hydrochloride Combined With Immunotherapy Maintenance Therapy Following Standard Chemoimmunotherapy for ES-SCLC (ALTER-L059)

Not yet recruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Small Cell Lung Cancer Extensive Stage

All Listed Sponsors

lead

Yong Fang

OTHER